With his broad expertise as biotech entrepreneur, Claus serves as CBO of AdvanceCor. Claus is a serial entrepreneur in the Life Sciences with 20 years’ experience in the Industry. In 2001, he cofounded Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and executed the listing of the Company at NASDAQ (PIRS) as CFO, playing a key role in transforming Pieris from a biotech Start-up to a mature biopharmaceutical company. Claus also cofounded XL-protein GmbH and led the Company to profitability through a series of collaborations with Pharma and Biotech.
Claus also supports other biotech companies in part-time management positions. He holds a Master degree in Business Administration from the University of Bamberg, Germany.
Martin Lohse leitet ISAR Bioscience. Er studierte Medizin und Philosophie an den Universitäten Göttingen, London und Paris und forschte an den Universitäten Bonn, Heidelberg, Durham (NC, USA) sowie am Genzentrum München. Seit 1993 ist er Professor für Pharmakologie an der Universität Würzburg, von 2016 bis 2019 leitete er das Max-Delbrück-Centrum in Berlin. Er ist außerdem Honorarprofessor für Biochemie an der FU Berlin.
Martin Lohse hat zahlreiche nationale und internationale Auszeichnungen erhalten, darunter den Leibniz-Preis, die höchste Auszeichnung in der deutschen Wissenschaft. Er ist Mitglied vieler Wissenschaftsakademien und war von 2009 bis 2019 Vizepräsident der Nationalen Akademie der Wissenschaften Leopoldina. Seit 2019 ist er Präsident der Gesellschaft Deutscher Naturforscher und Ärzte (GDNÄ).
Martin Lohse gehört zu den Gründern der Biotechnologiefirmen ProCorde, CorImmun und AdvanceCOR. Seine wissenschaftlichen Interessen gelten der Arzneimittelforschung und besonders der Erforschung von Rezeptoren als Angriffspunkte für neuartige Arzneimittel gegen Erkrankungen des Herz-Kreislauf-Systems und des Nervensystems.
After completing his medical studies at the Technischen Universität München (TUM, Germany), Meinrad Paul Gawaz has entered his clinical and academic career in the field of cardiology and cardiovascular science. He has become an international renowned clinician and vascular biologist.
Since October 2004, he has been appointed as Medical Director of the department of Internal Medicine III, cardiology and angiology at the University Hospital of Tübingen and as full professor (C4) of internal medicine/cardiology/angiology at the Eberhard Karls Universität of Tübingen.
The focus of his scientific work is on mechanisms of inflammation and thrombosis and antithrombotic therapy in cardiovascular disease. He is one of the leading experts in the field of platelet research. His clinical work concentrates on interventional cardiology and structural heart disease.
In 2004 Meinrad Gawaz was awarded the Alexander Schmidt Price (Thrombosis and Hemostasis Research Society) and in 2022 the Paul-Morawitz-Price (German Society for Cardiology). The price is awarded to physicians from German-speaking countries for outstanding research achievements in the field of cardiology. In 2023 he received the Rudolf Schönheimer Medal (German Atherosclerosis Society) for his eminent contribution to the atherosclerosis research.
Götz Münch is co-founder and managing director of advanceCOR GmbH, Martinsried, a Biotech company dedicated to the development of cardiovascular drugs. He was co-founder and managing director of Corimmun GmbH, which was successfully sold to Johnson & Johnson in 2012. Previously, he founded and managed ProCorde GmbH, where he was responsible for the site in Martinsried after successful merger with the English Biotech company TRIGEN (London, UK) from 2005.
After completion of his MD thesis at the Pharmacology Department of the University Freiburg at Prof. Dr. K. Starke and at the University College London at Prof. Dr. G. Burnstock in 1992, he made his PhD (Habilitation) in 2004 in Pharmacology at the University Würzburg. Since 2012 he is appointed assistant professor at the University of Würzburg.
He is consultant (Facharzt) for Internal Medicine and Cardiology and is lecturer in Biomedicine at the Julius-Maximilians-Universität Würzburg and teaches in the field of physiology/pathophysiology since 2001.
Götz is currently responsible for investor relations and the general funding and strategy of advanceCOR as Chief Executive officer. He is mainly responsible for the clinical development of the projects at advanceCOR. He planned and managed one phase I and two phase II multi-national studies as sponsor of the trial and in cooperation with an investigator-initiated study. He took the role of the Clinical Research Physician responsible for the design, preparation of the study including the approval with ethic committees and drug authorities and pharmacovigilance during the course of the study.